| Galderma Research & Development Patent applications |
| Patent application number | Title | Published |
|---|
| 20120035123 | COMBINATION OF COMPOUNDS FOR TREATING OR PREVENTING SKIN DISEASES - A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described. | 02-09-2012 |
| 20120021017 | N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 01-26-2012 |
| 20120021016 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 01-26-2012 |
| 20120016031 | BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS - Biphenyl compounds having the formula (I): | 01-19-2012 |
| 20110319491 | ANHYDROUS DEPIGMENTING COMPOSITIONS COMPRISING, WITHIN THE FATTY PHASE THEREOF, A SOLUBILIZED PHENOLIC COMPOUND AND A RETINOID - Novel anhydrous dermatological depigmenting compositions, especially for topical application, contain, within the fatty phase thereof, as pharmaceutical active agents, a dissolved phenolic compound and a retinoid. | 12-29-2011 |
| 20110318396 | DERMATOLOGICAL/COSMETIC COMPOSITIONS COMPRISING A RETINOID AND BENZOYL PEROXIDE - Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds. | 12-29-2011 |
| 20110311466 | NOVEL 4-(AZACYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS - 4-(azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: | 12-22-2011 |
| 20110305654 | ANHYDROUS PETROLEUM JELLY/ELASTOMER-FREE DEPIGMENTING COMPOSITIONS COMPRISING A SOLUBILIZED PHENOLIC COMPOUND - Novel dermatological depigmenting compositions, especially for topical application, contain as pharmaceutical active agents a dissolved phenolic compound, formulated as anhydrous compositions free of petroleum jelly and free of elastomer. | 12-15-2011 |
| 20110281913 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS - Melanocortin receptor antagonist compounds, processes for preparing them and uses thereof in human medicine and cosmetics are described. | 11-17-2011 |
| 20110275657 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS - Melanocortin receptor modulators, processes for preparing them and use thereof in human medicine and cosmetics are described. Melanocortin receptor modulators corresponding to formula (I): | 11-10-2011 |
| 20110275075 | SOX MODULATORS IN THE TREATMENT OF ALOPECIA - An in vitro method for screening candidate compounds for the preventive or curative treatment of alopecia is described. The method can include determining the capacity of a compound to modulate the expression or the activity of a SOX transcription factor. The use of modulators of the expression or the activity of the transcription factor for the treatment of alopecia is also described. Methods for the in vitro diagnosis or prognosis of the pathology are also described herein. | 11-10-2011 |
| 20110274727 | DEPIGMENTING TOPICAL COMPOSITIONS AND THEIR USES - Depigmenting topical compositions and their uses are described. In particular, the described compositions can provide improved effectiveness in the dermatological treatment of pigmentation, without disadvantages experienced with other known compositions. The described topical compositions can comprise, in a physiologically acceptable medium, from 3% to 10% of rucinol or one of its salts. Also described, are methods of use treating pigmentation disorders of the skin with the described compositions. | 11-10-2011 |
| 20110274638 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS - Compounds derived from oxoazetidine corresponding to general formula (I) | 11-10-2011 |
| 20110268742 | PCTP MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the phosphatidylcholine transfer protein (PCTP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 11-03-2011 |
| 20110263677 | GOS2 MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of G0/G1 switch protein 2 (GOS2), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 10-27-2011 |
| 20110256078 | COSMETIC/DERMATOLOGICAL COMPOSITIONS COMPRISING NAPHTHOLIC ACID COMPOUNDS AND POLYURETHANE POLYMERS - Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein. | 10-20-2011 |
| 20110236893 | LGR5 MODULATORS IN THE TREATMENT OF ALOPECIA - An in vitro method of screening for candidate compounds for the preventive or curative treatment of alopecia, which comprises determining the ability of a compound to modulate the expression or the activity of the LGR5 receptor is described. The use of modulators of the expression or of the activity of this receptor for treating alopecia is also described. In addition, methods for the diagnosis or prognosis, in vitro, of this disease are described. | 09-29-2011 |
| 20110229423 | PACAP SIGNALING PATHWAY MODULATORS FOR TREATING INFLAMMATORY SKIN DISEASES HAVING A NEUROGENIC COMPONENT, NOTABLY ROSACEA, AND COMPOSITIONS COMPRISED THEREOF - Modulators of specific PACAP receptors are useful for treating inflammatory skin diseases having a neurogenic component, and more particularly rosacea and/or facial erythema, compositions containing these and screening methods are described for identifying PACAP signaling pathway modulators. | 09-22-2011 |
| 20110224243 | FZD2 Molulators in the Treatment of Alopecia - An in vitro method for screening candidate compounds for the preventive or curative treatment of alopecia is described. The method can include determining the capacity of a compound to modulate the expression or the activity of a Frizzled 2 (FZD2) transmembrane receptor. Also described, is the use of modulators of the expression or the activity of the transmembrane receptor for the treatment of alopecia. Methods for the in vitro diagnosis or prognosis of this pathology are also described. | 09-15-2011 |
| 20110218506 | AMOROLFINE PATCH FOR THE TREATMENT OF ONYCHOMYCOSIS - A transungual patch/device useful for the treatment of onychomycosis includes:
| 09-08-2011 |
| 20110213009 | ADFP MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the adipose differentiation-related protein (ADFP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 09-01-2011 |
| 20110189686 | SCREENING FOR MODULATORS OF CYP2B15 AND/OR GPD1 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CYP2B15 and/or glycerol-3-phosphate dehydrogenase 1 (GPD1) proteins. | 08-04-2011 |
| 20110183943 | CONCURRENT THERAPY REGIME/REGIMEN FOR THE TREATMENT OF ACNE RELATED DISEASES - A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy. | 07-28-2011 |
| 20110165168 | CIDEA MODULATORS IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CIDEA protein, and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 07-07-2011 |
| 20110152372 | ANHYDROUS PETROLEUM JELLY/ELASTOMER-FREE DEPIGMENTING COMPOSITIONS COMPRISING A SOLUBILIZED PHENOLIC COMPOUND AND A RETINOID - Novel dermatological depigmentation compositions, especially for topical application, contain as pharmaceutical active agents a dissolved phenolic compound and a retinoid, formulated as anhydrous compositions free of petroleum jelly and free of elastomer. | 06-23-2011 |
| 20110150774 | SCREENING FOR MODULATORS OF CES1 AND/OR CES3 FOR THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the carboxylesterase 1 (CES1) and/or carboxylesterase 3 (CES3) proteins. | 06-23-2011 |
| 20110150773 | MODULATORS OF ACETYL-COENZYME A ACYLTRANSFERASE 1 OR 2 IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of acetyl-coenzyme A acyltransferase 1 (ACAA1) or of acetyl-coenzyme A acyltransferase 2 (ACAA2), and also utilizes modulators of the expression or of the activity of either of these enzymes, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 06-23-2011 |
| 20110150772 | MODULATORS OF CARNITINE OCTANOYLTRANSFERASE IN THE TREATMENT OF ACNE, OF SEBORRHOEIC DERMATITIS OR OF HYPERSEBORRHOEA - An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of carnitine octanoyltransferase (CROT), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured. | 06-23-2011 |
| 20110135584 | PHARMACEUTICAL/COSMETIC, E.G., ANTI-ACNE COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID COMPOUND, BENZOYL PEROXIDE AND AT LEAST ONE FILM-FORMING AGENT - Stable pharmaceutical/cosmetic compositions for topical application, notably for the treatment of acne vulgaris include, formulated into a physiologically acceptable medium, at least one naphthoic acid compound, benzoyl peroxide and at least one film-forming agent, the at least one naphthoic acid compound and the benzoyl peroxide advantageously being in a dispersed form therein. | 06-09-2011 |
| 20110130461 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 06-02-2011 |
| 20110070176 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 03-24-2011 |
| 20110027204 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 02-03-2011 |
| 20110003894 | DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS - Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris. | 01-06-2011 |
| 20100324111 | COMBINATION COMPRISING PYRROLIDONE-5-CARBOXYLIC ACID AND AT LEAST ONE COMPOUND FROM CITRULLINE, ARGININE AND ASPRAGINE, AND USE THEREOF IN THE TRATMENT OF ATOPIC DERMATITIS - The present invention relates to a composition comprising, in a physiologically acceptable carrier, pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, in racemic or isomer form, and salts thereof, for the preparation of a medicament for use in the treatment and/or prevention of atopic dermatitis. | 12-23-2010 |
| 20100292296 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS - Novel ligand compounds having the general formula (I): | 11-18-2010 |
| 20100286430 | METHOD FOR THE SYNTHESIS OF (Z)-3-[2-BUTOXY-3'-(3-HEPTYL-1-METHYL-UREIDO)-BIPHENYL-4-YL]-2-METHOXY-AC- RYLIC ACID - The invention relates to a process for the synthesis of (Z)-3-[2-butoxy-3′-(3-heptyl-1-methylureido)biphenyl-4-yl]-2-methoxyacrylic acid of formula (I): | 11-11-2010 |
| 20100286285 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state - The present invention relates to an anhydrous pharmaceutical composition for use in the treatment of psoriasis and other skin disorders, characterized in that it comprises an oleaginous ointment and, as active ingredient, a compound chosen from vitamin D and its derivatives, said active agent being in a solubilized form in said composition. | 11-11-2010 |
| 20100280121 | PRODUCTION OF ADAPALENE GELS - A method for producing an adapalene aqueous gel on an industrial scale including formulating a gelling medium A by mixing water and propylene glycol and adding a gelling agent thereto; formulating an adapalene medium B by dispersing adapalene in water, in the presence of a surfactant; next adding the adapalene medium B to the gelling medium A; and adjusting the pH to about 4.7-5.3. | 11-04-2010 |
| 20100273883 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof - Novel ligand compounds having the structural formula (I): | 10-28-2010 |
| 20100273882 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 10-28-2010 |
| 20100273813 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 10-28-2010 |
| 20100261754 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS - The invention relates to compounds corresponding to general formula (I) below: | 10-14-2010 |
| 20100260736 | EGR1 MODULATORS FOR THE TREATMENT OF ALOPECIA - An in vitro method of screening of candidate compounds for the preventive or curative treatment of alopecia includes determination of the capacity of a compound to modulate the expression or activity of the Early Growth Response 1 transcription factor (EGR1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of alopecia; such method also includes in vitro diagnosis or prognosis of this pathology. | 10-14-2010 |
| 20100247583 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 09-30-2010 |
| 20100247468 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds - Novel compounds having the general formula (I) below: | 09-30-2010 |
| 20100233718 | NON-INVASIVE TECHNIQUE FOR CONDUCTING SKIN INFLAMMATORY DISEASE PHARMACO-GENOMIC STUDIES AND DIAGNOSES THEREOF - Non-invasive techniques to conduct skin inflammatory disease pharmaco-genomic studies and diagnoses thereof feature discriminating biomarkers and genes and in vitro diagnostic methods employing such biomarkers. | 09-16-2010 |
| 20100222431 | NOVEL PHENYLUREA INHIBITORS OF THE SOAT-1 ENZYME AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel phenylurea compounds of formula (I): | 09-02-2010 |
| 20100222333 | EXCIPIENT PRESERVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF - Topically applicable pharmaceutical compositions contain at least one pharmaceutically active agent and an effective antimicrobial amount of a preservative excipient mixture and devoid of such amount of known preservative(s) as would otherwise itself impart an effective antimicrobial action thereto. | 09-02-2010 |
| 20100210994 | DELIVERY OF THERAPEUTICALLY/DERMATOLOGICALLY ACTIVE SPECIES INTO THE SKIN VIA ELECTROPORATION - A regime or regimen for treating a skin disease, disorder or condition afflicting a patient in need thereof includes forming at least one micropore to a predetermined depth through a surface of the afflicted skin of such patient; positioning at least a first electrode on the surface of the afflicted skin electrically coupled to the at least one micropore and a second electrode on the surface of the afflicted skin spaced apart from the first electrode; applying an electrical voltage from the first and second electrodes to produce a desired electroporation in the skin, and further including the step of delivering a biologically active species to the afflicted skin at the at least two micropores formed therein, wherein the biologically active species is therapeutically/dermatologically active against the skin disease, disorder or condition. | 08-19-2010 |
| 20100197735 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel phenylurea compounds of formula (I): | 08-05-2010 |
| 20100190853 | TOPICAL APPLICATION OF TRAVOPROST FOR COMBATING HAIR LOSS - Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours. | 07-29-2010 |
| 20100183741 | DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE - Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: | 07-22-2010 |
| 20100179209 | Pactimibe medicaments for preventing/treating a disease due to sebaceous gland dysfunction in humans or animals - Administration of at least one compound selected from N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (pactimibe) of formula (I): | 07-15-2010 |
| 20100172957 | EFLUCIMIBE MEDICAMENTS FOR PREVENTING/TREATING A DISEASE DUE TO SEBACEOUS GLAND DYSFUNCTION IN HUMANS OR ANIMALS - Administration of at least one compound selected from (S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetanilide (eflucimibe) of formula (I): | 07-08-2010 |
| 20100168241 | TREATMENT OF ACNE DISEASE STATES, NOTABLY ACNE VULGARIS - Acne disease states, notably acne vulgaris, are treated with naphthoic acid compounds and particularly adapalene in association/combination with light therapy. | 07-01-2010 |
| 20100168231 | TARGET ENZYME FOR THE TREATMENT OF ACNE - The use of an enzyme as a research tool for acne, by identifying a compound for the treatment of acne and/or any disorder associated with cutaneous hyperseborrhoea. | 07-01-2010 |
| 20100168089 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE - An in vitro method of screening for candidate compounds for the preventive or curative treatment of acne entails determination of the ability of a compound to inhibit the expression or the activity of TACE, and also to the administration of inhibitors of the expression or of the activity of this enzyme, in the treatment of acne. | 07-01-2010 |
| 20100166852 | Cream gels comprising at least one retinoid and benzoyl peroxide - The invention relates to a composition in the form of a cream gel comprising, in a physiologically acceptable medium, at least one dispersed retinoid and dispersed benzoyl peroxide, to its process of preparation and to its use in cosmetics and in dermatology. | 07-01-2010 |
| 20100160439 | DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, AN ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE - Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: | 06-24-2010 |
| 20100158843 | NOVEL 3-PHENYLPROPANOIC COMPOUND ACTIVATORS OF RECEPTORS OF PPAR TYPE AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel 3-phenylpropanoic acid compounds have the general formula (I) below: | 06-24-2010 |
| 20100145105 | NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF - Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): | 06-10-2010 |
| 20100144884 | NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel 3-phenyl acrylic acid compounds have the following general formula (I): | 06-10-2010 |
| 20100144814 | NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF - Novel 4-phenylimidazole-2-thione tyrosinase inhibiting compounds corresponding to the following general formula (I): | 06-10-2010 |
| 20100144813 | NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF - Novel 4-heteroarylimidazole-2-thione tyrosinase inhibiting compounds corresponding to the following general formula (I): | 06-10-2010 |
| 20100143446 | Novel skin moisturizing compositions - Novel skin moisturizing compositions are applied onto dry skin, particularly mild to moderately dry skin, are non-irritating and contain at least one natural moisturizing factor, | 06-10-2010 |
| 20100143445 | Dermatological/cosmetic skin depigmenting compositions - Depigmenting compositions having improved effectiveness in the dermatological or cosmetic treatment of pigmentation contain, in a physiologically acceptable medium, at least one compound selected from among rucinol and salts thereof, and at least one retinoid; such compositions are also useful in the prevention and/or dermatological treatment of skin hyperpigmentation, and also for the cosmetic treatment of photoinduced or chronological aging of the skin or of the skin appendages. | 06-10-2010 |
| 20100130614 | ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF IL-1ra - Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of IL-1ra by the cells of acneic epidermis. | 05-27-2010 |
| 20100130613 | ADMINISTRATION OF ADAPALENE FOR MODULATING THE EXPRESSION OF CD1d OR IL-10 - Adapalene or pharmaceutically acceptable salt thereof is administered to an individual in need of such treatment for modulating the expression of CD1d or IL-10 in an inflammatory acneic lesion. | 05-27-2010 |
| 20100124538 | TOPICAL APPLICATION OF FLUOCINOLONE ACETONIDE FOR DEPIGMENTATION OF THE SKIN - Topically applicable compositions useful for the depigmentation of the skin contain a fluocinolone acetonide depigmenting agent, at a concentration of from 0.0001% to 0.02% by weight, of the total weight of the composition, formulated into physiologically acceptable carrier therefor. | 05-20-2010 |
| 20100099689 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS - Novel compounds having the general formula (I) below: | 04-22-2010 |
| 20100087669 | NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF - Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): | 04-08-2010 |
| 20100069495 | Topical application of adapalene for the long-term treatment of acne vulgaris - Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months. | 03-18-2010 |
| 20100057369 | Corrective methodology for processing results of transcriptome experiments obtained by differential analysis - A corrective method for processing results of transcriptome experiments obtained by differential analysis includes the following steps:
| 03-04-2010 |
| 20100035988 | Methods for activating PPAR gamma-type receptors - Novel biaromatic compounds having the following structural formula (I): | 02-11-2010 |
| 20100028879 | Modulators of HSD17b7 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of hydroxysteroid (17-beta) dehydrogenase type 7, and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or in vitro prognosis of these pathologies are also described. | 02-04-2010 |
| 20100028878 | Modulators of UDP-glucose ceramide glucosyltransferase for treating acne or hyperkeratinization - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of UDP-glucose ceramide glucosyltransferase (UGCG), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperkeratinization; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 02-04-2010 |
| 20100022642 | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide - Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds. | 01-28-2010 |
| 20100021893 | Modulators of lanosterol synthetase for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of lanosterol synthetase (LSS), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 01-28-2010 |
| 20100021892 | Modulators of SC4MOL for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of sterol-C4-methyl oxidase (SC4MOL), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 01-28-2010 |
| 20100010049 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof - Compounds corresponding to the following general formula (I): | 01-14-2010 |
| 20090318550 | Emulsions comprising at least one retinoid and benzoyl peroxide - Stable dermatological/cosmetic emulsions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one fatty phase, at least one hydrophilic phase and at least one emulsifier. | 12-24-2009 |
| 20090305209 | Online protocol/tool for evaluating acne lesions - A web-based protocol/tool to improve the identification and characterization process of evaluators in recognizing and distinguishing acne lesions, included at least the following program activities:
| 12-10-2009 |
| 20090298798 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 12-03-2009 |
| 20090298074 | Modulators of ELOVL5 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of ELOVL5 and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 12-03-2009 |
| 20090281188 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 11-12-2009 |
| 20090258356 | Modulators of the transporter ABCD3 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the peroxisome membrane transporter 1 comprising a type 3 ATP-binding site of the sub-family D (ABCD3), and the use of modulators of the expression or activity of this transporter for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 10-15-2009 |
| 20090253788 | Combinations of adapalene and benzoyl peroxide for treating acne lesions - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 10-08-2009 |
| 20090246776 | Modulators of scarb-1 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the SCARB-1 receptor, and the use of modulators of the expression or activity of this receptor for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 10-01-2009 |
| 20090191245 | REDUCED-IRRITANT DERMATOLOGICAL COMPOSITIONS COMPRISING AT LEAST ONE NAPHTHOIC ACID COMPOUND AND BENZOYL PEROXIDE AND TREATMENT OF KERATINIZATION DISORDERS THEREWITH - Topically applicable, reduced-irritant dermatological/cosmetic compositions useful for the prevention/treatment of a variety of keratinization disorders, for example acne vulgaris, contain at least one naphthoic acid compound and an amount of benzoyl peroxide encapsulated in a polymeric system of porous particles for increasing cutaneous penetration of the at least one naphthoic acid compound, are formulated into topically applicable, physiologically acceptable media therefor. | 07-30-2009 |
| 20090137569 | Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions - Inflammatory skin pathologies/afflictions, e.g., eczema or psoriasis, are prevented and/or treated by administering to a subject in need of such treatment, a thus effective amount of at least one compound of following formula (I): | 05-28-2009 |
| 20090098219 | Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith - Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among is allantoin, divalent strontium salts, divalent zinc salts, monovalent sodium salts and the hydrated derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris. | 04-16-2009 |
| 20090088460 | Administration of E-3[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(3-pyridyl- )propenohydroxamic acid for preventing and/or treating inflammatory cutaneous pathologies/afflictions - Inflammatory cutaneous pathologies/afflictions, e.g., eczema or psoriasis, are prevented and/or treated by administering to a subject in need of such treatment, a thus effective amount of E-3-[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(3-pyridyl)propenohydroxamic acid of formula (I): | 04-02-2009 |
| 20090062340 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF - Novel biaromatic compounds having the structural formula (I) below: | 03-05-2009 |
| 20090048289 | ADMINISTRATION OF TROPISETRON FOR TREATING INFLAMMATORY SKIN DISEASES/DISORDERS - Tropisetron or salt thereof, formulated into diverse pharmaceutical/dermatological compositions, is useful for the treatment of a variety of inflammatory skin disorders/diseases, e.g., eczema, psoriasis, rosacea, acne vulgaris, ulcers, seborrhoeic dermatitis and irritations induced by chemical, physical or mechanical agents, notably rosacea. | 02-19-2009 |
| 20090036536 | Biphenyl compound selective agonists of gamma RAR receptors - Biphenyl compounds having the formula (I): | 02-05-2009 |
| 20090023811 | Biphenyl compound selective agonists of gamma RAR receptors - Biphenyl compounds having the formula (I): | 01-22-2009 |
| 20090018102 | Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars. | 01-15-2009 |
| 20090012172 | Cosmetic/pharmaceutical compositions comprising retinoids and anti-irritants and treatment of keratinization disorders therewith - Topically applicable cosmetic/pharmaceutical compositions contain at least one retinoid and at least one anti-irritant compound selected from among the salts of 18β-glycyrrhetinic acid and derivatives thereof, and are useful for the treatment and/or prevention of a dermatological condition or affliction related to a disorder of keratinization relating to cell differentiation and to cell proliferation, e.g. acne vulgaris. | 01-08-2009 |
| 20090012129 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS - Novel biaromatic compounds that modulate peroxisome proliferator-activator receptors, known as PPAR, having the formula (I): | 01-08-2009 |
| 20090004232 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF - Physically stable pharmaceutical/cosmetic compositions contain at least one hydrophilic phase, at least one lipophilic phase and at least one active principle, e.g., at least one steroidal anti-inflammatory agent, anti-fungal agent, anti-parasitic agent, nuclear receptor modulator and/or sex steroid, said at least one active principle being present in dissolved state in each of these phases; these are formulated via characteristic multi-step methodology. | 01-01-2009 |
| 20080305060 | AQUEOUS-ALCOHOLIC DEPIGMENTING GELS - Stable, topically applicable cosmetic/pharmaceutical skin depigmenting compositions contain at least one phenolic compound, at least one retinoid and at least one corticoid, and are formulated as aqueous-alcoholic gels in topically applicable, physiologically acceptable media therefor. | 12-11-2008 |
| 20080253986 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers - Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein. | 10-16-2008 |
